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Purpose: This study was intended to describe the risk of epilepsy subsequent to posterior reversible
encephalopathy syndrome (PRES) and the clinical features of post-PRES epilepsy.
Method: We retrospectively identiﬁed all patients with PRES who were admitted to Severance Hospital
and consulted with the Department of Neurology between 2001 and 2013 and the subgroup of these
patients who subsequently developed epilepsy. We also describe clinical features of patients who were
not treated with PRES as inpatients at our center but who presented later with post-PRES epilepsy during
the study period. We studied clinical characteristics during the acute symptomatic phase of PRES and
after the development of epilepsy.
Results: During the study period 102 patients were treated at our center during the acute phase of PRES.
Four of these patients (3.9%) subsequently developed epilepsy. Two additional patients with a history of
PRES presented to our hospital after the acute phase of their illness with post-PRES epilepsy. During the
acute phase, ﬁve of six patients had acute symptomatic seizures and four had convulsive or
nonconvulsive status epilepticus (SE). Acute phase MRI showed cytotoxic edema in ﬁve patients, and
follow-up MRI showed focal atrophic changes including hippocampal sclerosis in four. Presumptive
epileptogenic foci were located in the left-side temporal, parietal and occipital lobes, corresponding to
the regions that showed cytotoxic edema or severe vasogenic edema as well as with the location or
lateralization of EEG abnormalities during the acute phase.
Conclusion: Our ﬁndings indicate a small but not insigniﬁcant risk for the development of epilepsy after
PRES. The presence of cytotoxic edema and severe, acute symptomatic seizures, such as SE suggests
irreversible brain damage and may predict the development of epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Posterior reversible encephalopathy syndrome (PRES) presents
with various neurological signs and symptoms, including seizures,
and is characterized by a pattern of abnormalities in brain imaging
studies. The prognosis in patients with PRES is favorable as most
cases completely resolve without any sequelae [1] if theAbbreviations: PRES, posterior reversible encephalopathy syndrome; AED, antiepi-
leptic drug; SE, status epilepticus; HS, hippocampal sclerosis; GTCS, generalized
tonic-clonic seizure; PLED, periodic lateralized epileptiform discharge; FLAIR, ﬂuid-
attenuated inversion recovery; DW, diffusion-weighted; HE, hypertensive enceph-
alopathy; TLE, temporal lobe epilepsy.
* Corresponding author at: Department of Neurology, Epilepsy Research
Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Republic of Korea.
E-mail address: kheo@yuhs.ac (K. Heo).
http://dx.doi.org/10.1016/j.seizure.2015.12.005
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reunderlying conditions responsible for PRES are treated promptly.
Recently, two studies showed that the development of epilepsy is
uncommon in patients who recover from PRES [2,3]. However,
cytotoxic edema (bright signals on diffusion weighted imaging,
dark signals on apparent diffusion coefﬁcient map images),
hemorrhage, contrast enhancement on MRI during the acute
symptomatic phase, and residual lesions on follow-up MRI are not
infrequently found in PRES [4–8]. As well, pathologic evidence of
partial irreversible damage has been documented in PRES in spite
of radiographic resolution of abnormalities [9], suggesting the
potential for irreversible brain damage. Although seizures occur-
ring during the acute symptomatic phase, are generally well
controlled by short-term antiepileptic drug (AED) treatment [10],
severe seizures such as status epilepticus (SE), and delayed or non-
aggressive treatment of seizures may produce irreversible injury.
Herein, we attempted to investigate the risk of epilepsy subse-
quent to PRES, describe the clinical characteristics of patients whoserved.
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K. Heo et al. / Seizure 34 (2016) 90–94 91developed epilepsy after PRES, and discuss associated risk factors
for this condition.
2. Methods
In order to estimate the incidence of epilepsy development
stemming from PRES, we retrospectively identiﬁed all patients
with PRES who were admitted to Severance Hospital and consulted
with the Department of Neurology between January 2001 and
December 2013 from data maintained by our department.
Diagnosis of PRES was based on clinical features (predisposing
conditions, headache, seizures, alterations in consciousness, and
visual abnormalities); multifocal lesions on MRI, mainly suggest-
ing vasogenic edema; clinical recovery; and when available,
reversibility of MRI lesions. We identiﬁed six patients with
epilepsy following PRES, who visited the epilepsy clinic of
Severance Hospital between January 2001 and December 2014. Ad-
ditionally, we searched the medical records of patients with PRES
who were admitted to our hospital, and investigated evidence of
seizure or epilepsy occurrence. Clinical information was collected
for these six patients including demographics, co-morbid illnesses,
medication histories, neurological manifestations, brain MRI, and
EEG during the acute symptomatic phase of PRES. Clinical
information on seizure semiology, EEG, brain MRI and prognosis
after the development of epilepsy was investigated in detail. This
study was approved by the Institutional Review Board of Severance
Hospital.
3. Results
3.1. Overall incidence of epilepsy in patients with PRES
We identiﬁed 102 patients who were treated at our hospital
during the acute phase of PRES. Four of these patients (3.9%)
developed epilepsy subsequent to PRES. We did not ﬁnd evidence
of seizure or epilepsy occurrence in any other patients among the
medical records of our hospital. Two additional patients (Patients
2 and 3) suffering from PRES who were admitted to other hospitals,
developed intractable epilepsy and a single seizure, respectively,
and visited the epilepsy clinic of our hospital.
3.2. Clinical features of patients in the acute phase of PRES
The clinical data for the patient cohort are described in
Table 1. All patients except for Patient 3 had acute symptomatic
seizures. Four patients (Patients 1, 2, 5 and 6) had convulsive or
nonconvulsive SE. Patient 1 had recurrent episodes of deviation of
the head and eyes to the right and hand automatisms without
responsiveness for one day. Patient 2 showed a continuous state of
the head and eyes to the right or motionless staring without
responsiveness for 4 h. In Patient 5, recurrent episodes of deviation
of the head and eyes to the right and clonic movements of bilateral
shoulders (more prominent in the right side) with intermittent
generalization were found in a state of persistent deterioration of
consciousness for 2 days.
Acute phase MRI revealed cytotoxic edema in ﬁve patients
(except for Patient 2). The MRI of Patient 2 showed all lobar
involvement predominantly in the left hemisphere on MRI
without cytotoxic edema during the acute phase although the
brain MRI scans were not available due to the disposal of the old
data. Patient 6 developed four generalized tonic-clonic seizures
for 1 h in the initial period of PRES, followed by recurrent episodes
of eye and head deviation to the right side, intermittently evolving
to convulsive movements of the right face and arm in the state of
persistent deterioration of consciousness for a prolonged time. He
received delayed and non-aggressive AED treatment. Frequent 
K. Heo et al. / Seizure 34 (2016) 90–9492seizures persisted for approximately 1 month although his high
blood pressure was controlled, tacrolimus was temporarily
stopped and then its dose was decreased. The MRI of Patient 6,
performed 24 days after the initial MRI during the acute phase of
PRES, showed a slight improvement of the lesions noted on the
initial MRI; however, increases in the size or new lesions in the left
temporo-occipital lobes (which exhibited cytotoxic edema on the
initial MRI) were considered as seizure-induced changes super-
imposed on unresolved PRES (Fig. 1). Additional clinical informa-
tion on Patient 1 was described in detail in our previous paper
[11].
3.3. Clinical features of patients after the development of epilepsy
As shown in Table 2, the duration from PRES to the
development of epilepsy varied and was within 1 year of the
acute phase of PRES, except for Patient 3. Patient 3 who did not
have acute symptomatic seizure or residual MRI changes,
developed her ﬁrst seizure 7 years after PRES. All patients,
except for Patient 6, developed seizures in the absence of AED
treatment. Patient 6 with prolonged SE and additional seizure-
induced MRI changes during the acute phase developed habitual
seizures immediately after PRES. Patient 1 had residual focal
neurological deﬁcits of the right homonymous inferior quad-
rantanopia and numbness in her right lower extremity. PatientFig. 1. Brain magnetic resonance images (MRIs) during the acute period and follow-up
reversible encephalopathy syndrome (PRES). Reproduced from reference [11] with per
epilepsy. Reproduced from reference [11] with permission from Karger. (C) T2-weighted 
recovery (FLAIR) and DW images of Patient 3 with PRES. (E) FLAIR and DW images of Pat
FLAIR and DW images of Patient 5 with PRES. (H) FLAIR and DW images of Patient 6 wit
Patient 6, 2 years after the initial MRI. See Tables 1 and 2, and text for information.2 who underwent neuropsychological testing, had borderline or
low-average verbal memory but better visual memory. Patient
6 complained of decreased memory function, difﬁculty ﬁnding
words, and right homonymous hemianopsia. Follow-up MRI after
epilepsy development showed focal atrophic changes including
hippocampal sclerosis (HS) in four patients (Patients 1, 2, 4 and
6). Presumptive epileptogenic foci were located in the left-side
temporal, parietal and occipital lobes, corresponding to the
regions that showed cytotoxic edema (Patient 1, 3, 4, 5 and 6) or
severe vasogenic edema (Patient 2) on MRIs as well as with the
location or lateralization of EEG abnormalities during the acute
phase.
Brain MRIs obtained during the acute phase and follow-up are
shown in Fig. 1.
3.4. Seizure outcome
Patient 1 had experienced intermittent auras only or simple
partial seizures over a period of 13 years and 3 months with
phenytoin treatment, which began after a single secondarily
generalized tonic-clonic seizure, and attained seizure freedom
with levetiracetam treatment over the past 7 months. Patient 2 had
visited our epilepsy clinic because of drug-resistant epilepsy for
10 years. She declined epilepsy surgery because of concerns
about the risk of surgical treatment. She showed a signiﬁcant. (A) T2-weighted and diffusion-weighted (DW) images of Patient 1 with posterior
mission from Karger. (B) T2-weighted image of Patient 1 after the development of
image of Patient 2 after the development of epilepsy. (D) Fluid-attenuated inversion
ient 4 with PRES. (F) FLAIR image of Patient 4 after the development of epilepsy. (G)
h PRES. (I) FLAIR image of Patient 6, 24 days after the initial MRI. (J) FLAIR image of
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K. Heo et al. / Seizure 34 (2016) 90–94 93improvement in seizure frequency and severity with further AED
treatment (lacosamide, lamotrigine, topiramate and valproic acid)
over the past 3 years and 10 months. Patient 3 had maintained
seizure freedom over the past 3 years and 7 months with
lamotrigine treatment, which began after a single seizure. Patient
4 had experienced intermittent complex partial seizures or auras
only over the past 3 years and 9 months with AED treatment, which
began after a single secondarily generalized tonic-clonic seizure;
she attained seizure freedom with carbamazepine and topiramate
treatment over the past 8 months. Patient 5 was diagnosed as
having epilepsy after his second episode of aphasic status and had
maintained seizure freedom with levetiracetam treatment over the
past 5 years and 10 months. Patient 6 experienced monthly
complex partial seizures over the past 3 years and 2 months with
polytherapy (lamotrigine, levetiracetam, topiramate, and valproic
acid).
4. Discussion
Our ﬁndings suggested that PRES may lead to the development
of epilepsy in patients, particularly those with severe brain damage
during the acute phase although there is a small risk of epilepsy for
patients with PRES. In a nationwide population-based study from
the National Health Insurance Research Database of Taiwan, the
incidence of subsequent epilepsy was 2.25-fold higher in patients
with hypertensive encephalopathy (HE) than in hypertensive
patients without a history of HE (4.17 versus 1.85 per 1000 person-
years), with an adjusted hazard ratio of 2.06 (95% conﬁdence
interval = 1.66–2.56) [12]. However, the study cohort only
included patients with HE, did not include all patients with PRES
and did not provide any detailed information on patients with
epilepsy. In a retrospective study of 127 patients with PRES, whose
median duration of follow-up was 3.2 years, three (2.4%) patients
developed subsequent unprovoked seizures, and one of them had
recurrent seizures and was considered to have developed epilepsy
[2]. In another retrospective study of 75 patients with PRES, four
(5.3%) patients had seizures later than one month beyond their
hospitalization for PRES, and two of them developed chronic
epilepsy [3]. These ﬁndings suggest that PRES may be associated
infrequently with subsequent development of unprovoked sei-
zures and epilepsy.
Our study had several signiﬁcant limitations, including the
patient population from a single center, the small number of
patients, referral bias toward unusual or severe cases at a large
tertiary hospital, insufﬁcient capture of cases that might have led
to an underestimation of patients with PRES or epilepsy subse-
quent to PRES, lack of a pediatric population, and a short follow-up
period. Therefore, although the true incidence of the development
of epilepsy following PRES could not be assessed accurately, we
estimated the incidence of seizure or epilepsy following PRES to be
3.9%.
Six cases of temporal lobe epilepsy (TLE) with HS or occipital
lobe epilepsy following PRES or HE have been reported [13–16].
One of the ﬁve patients with HS had cytotoxic edema in the left
temporal lobe, including the mesial temporal structures on MRI
obtained during the acute phase [14], as seen in Patient 4 in our
study. One patient with HS did not have any MRI change in the
hippocampus on MRI during the acute phase [16]. The other
three patients with HS did not have an MRI performed during their
acute disease [13]. One patient with occipital lobe epilepsy had two
bilateral hematomas in the parieto-occipital region [15]. As well, a
retrospective study investigated 26 female patients with HS who
had no identiﬁable risk factors or seizures following pregnancy,
and found that nine had a history of eclampsia [17]. This ﬁnding
suggested that eclampsia might be a risk factor for TLE and HS,
K. Heo et al. / Seizure 34 (2016) 90–9494although information from MRIs that can be performed during the
eclamptic episodes was not described.
Evidence of irreversible damage may not be detected in most of
patients with PRES. However, cytotoxic edema and severe
vasogenic edema, which occur in some patients with PRES, may
suggest irreversible tissue damage that may or may not be
detectable on follow-up MRI. In this study, cytotoxic edema was
found in ﬁve out of six patients. Follow-up MRI showed focal
atrophic changes including HS in four patients. Presumptive
epileptogenic foci corresponded to the regions that showed
cytotoxic edema on MRIs during the acute phase.
Also, the role of SE in potential irreversible brain injury should
not be ignored. In this study, SE occurred in four patients. SE itself
may contribute to cytotoxic edema, which was found in three
patients. A previous report described the case of a boy who
presented with PRES and nonconvulsive SE after the initiation of
intrathecal methotrexate, who subsequently developed TLE with
HS [14]. Initial MRI revealed a patchy, relatively symmetric, T2
signal increase in subcortical regions of the posterior portions of
the cerebral and cerebellar hemispheres when the patient
developed PRES symptoms with probably several (although the
number of seizures was not described accurately) complex partial
seizures on day 8 after the ﬁrst dose of chemotherapy. Four days
later the patient developed nonconvulsive SE along with increased
blood pressure. Another MRI indicated extensive restriction of
diffusion signal involving the entire left temporal lobe, including
the mesial temporal structures, insular cortex and posterior
thalamus. As seen in Patient 6, SE or frequent seizures related to
delayed and non-aggressive treatment may contribute to brain
damage. On the other hand, the degree of PRES itself may be an
important factor for irreversible brain injury. Patients 4 and a
previously reported patient [16] had just two generalized tonic-
clonic seizures and probably several complex partial seizures,
respectively, suggesting that PRES itself could produce HS.
Irrespective of a lack of comparison with patients who did not
develop epilepsy, our ﬁndings suggest that cytotoxic edema on
MRI and SE during the acute phase may be risk factors for the
development of epilepsy. Therefore, prompt control of acute
symptomatic seizures associated with PRES, as well as general
treatment strategies for PRES, such as reduction of high blood
pressure, withdrawal or dose reduction of offending drugs, and
control of other associated underlying conditions or diseases, is
important for preventing the development of epilepsy.
Seizure outcome in patients with epilepsy following PRES may
not be benign. In this study, long-term seizure freedom was
attained in only two out of six patients, although an unfavorable
prognosis may be related to referral bias.
5. Conclusion
In conclusion, the results of this study suggest that the risk of the
development of epilepsy after PRES might be small but not
insigniﬁcant, although this study had several signiﬁcant limitations.The presence of cytotoxic edema on MRI and severe, acute
symptomatic seizures, such as SE during the acute phase, may
indicate and enhance irreversible brain damage and may predict the
development of epilepsy. Additional large prospective studies are
required to accurately determine the incidence of epilepsy following
PRES and to identify biological markers predictive of epilepsy
development.
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